Some data that physicians would like to see demonstrated in bioequivalence studies may not be feasible in clinical trials due to the number of patients who would have to be enrolled in the studies.
As novel therapies and biosimilars of existing biologics are being developed for the treatment of inflammatory bowel disease (IBD), an increasing number of bioequivalence, head-to-head, superiority, and non-inferiority trials are expected in the near future. In order to better understand physicians’ perspectives on the clinical meaningfulness of trial results in IBD, a research team, led by Pablo Olivera, MD, of the Centro de Educación Médica e Investigaciones Clínicas in Buenos Aires, Argentina, conducted an online survey of International Organization for the Study of Inflammatory Bowel Diseases (IOIBD) members (adult or pediatric gastroenterologists, surgeons, or pathologists specializing in IBD) to better understand their view of the clinical relevance of such trial results. The full results of the survey were published in Alimentary Pharmacology and Therapeutics.
A total of 88 IOIBD members were invited to take the survey, and 46 (52.3%) completed the questionnaire. Most of the participants, who resided in more than 20 countries, had over 20 years of clinical experience and worked in high-volume centers.
With respect to bioequivalence studies comparing an originator biologic to a biosimilar, most participants answered that a clinically important difference between groups would be as follows for:
The survey’s authors note that, although such data do not yet exist for studies of biosimilars specific to patients with IBD, results of equivalence studies of infliximab biosimilars (CT-P13 and SB2) for other immune-mediated diseases, which have led to approval for IBD indications by extrapolation, have used an equivalence margin of plus or minus 15%.
“An interesting observation from the results is that there is a disconnect between what physicians consider adequate, [and] what is feasible to demonstrate from the statistical point of view,” write the authors. For example, considering a statistical power of 80%, in order to demonstrate a 5% bioequivalence limit for all variables, the number of subjects required per group in the trial would be 822, write the authors, which would be “clearly very difficult to fulfill, and if implemented would limit access to biosimilars.”
The authors state that some of the data that physicians would like to see demonstrated may not be feasible in clinical trials due to the number of patients who would have to be enrolled in these studies. Given the fact that IBD is still relatively rare (compared with diseases such as hypertension or cardiovascular disease), a large population would be “difficult to impossible” to recruit.
“Finding a middle ground between what is desired in an ideal world and what it is feasible from a sample size/statistical perspective is necessary. In this regard, the results shown in this survey might influence the design of future IBD clinical trials,” the authors write.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Real-World Study: No Increase in Health Resource Costs After Infliximab Biosimilar Introduction
July 20th 2024Although biosimilars reduce drug purchasing costs for hospitals, it’s unclear whether those savings might be offset by increased health resource utilization following a non-medical switching initiative.
Biosimilars Gastroenterology Roundup for May 2024—Podcast Edition
June 2nd 2024On this episode of Not So Different, we review the biggest gastroenterology biosimilar stories from May 2024, covering new data from conferences and journals on infliximab and adalimumab products that demonstrate positive clinical results and confirm the safety of these biosimilars, as well as the feasibility of switching to them.
Trastuzumab-dkst Shows Promising Results in Real-World Setting for HER2+ Breast Cancer
July 9th 2024A Brazilian real-world study found trastuzumab-dkst to be an effective and safe adjuvant therapy for HER2-positive (HER2+) breast cancer, with clinical outcomes comparable to reference trastuzumab.